Short answer
Lyell Immunopharma Inc (LYEL) filed an 8-K current report with the SEC on August 6, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results announced for quarter ended June 30, 2026.
Lyell Immunopharma Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Detailed operating results and management commentary contained in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss $44.8M, up from $42.7M, reflecting heavier clinical investment and lower interest income
- Cash, equivalents and marketable securities $228.0M, supporting operations into Q3 2027 but leaving future financing risk
- Ronde-cel pivotal 3L+ data expected mid-2027, with BLA submission targeted for second half 2027
- Ronde-cel safety data in over 100 patients showed no Grade ≥3 CRS and low Grade ≥3 ICANS, supporting potential outpatient use
- LYL273 Grade ≥2 diarrhea or colitis fell from 55% to 10% with prophylaxis, enabling Phase 1/2 expansion and potential pivotal development
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Lyell Immunopharma Inc 8-K filings
Get the next LYEL 8-K as it lands
Follow LYEL for push alerts, or ask the research agent what this filing means.